Atripla (Efavirenz / Emtricitabine / Tenofovir)

Atripla in the United Kingdom is identical to Atripla in the United States. The strength of Atripla is also the same in both countries, however the packaging makes the strength look different. One ingredient in Atripla is Tenofovir, which is listed as 300mg on US packaging but 245mg on UK packaging. The reason for this is that the US measures the weight of the full salt Tenofovir Disoproxil Fumarate while the UK version measures the weight of Tenofovir Disoproxil (without the fumarate salt component). Both Atripla versions are absolutely identical.

Prescription Atripla is a 3 in 1 medicine containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Atripla is used alone or in combination with other medicines to treat HIV-1 infection by adults and children with a minimum weight of 88 pounds. All 3 ingredients of Atripla block the ability of the enzyme reverse transcriptase, which is produced by the HIV disease to cause further infection and spread. Atripla will keep HIV levels lower in the blood. Atripla is not a cure for AIDS or HIV but slows down the progression of the disease and damage to the immune system and conditions/diseases associated with AIDS.

Atripla is usually taken once per day on an empty stomach, usually at bedtime. Take Atripla regularly, exactly as prescribed and do not miss your daily Atripla dose.

In 2019, when comparing Atripla cost to USA Atripla coupon price, InsulinHub was found to offer a discount of approximately 40% in Atripla savings.

Buy Atripla from InsulinHub.com for the best Atripla cost.

Atripla (Efavirenz / Emtricitabine / Tenofovir)

Atripla is a fixed-dose combination medication used in the treatment of HIV-1 infection. Tenofovir NRTI that also inhibits reverse transcriptase and disrupts the HIV replication cycle.

Atripla is used as part of a comprehensive HIV treatment regimen to help control and reduce the viral load of HIV-1 in the body. It helps in improving the immune system and preventing the progression to AIDS.

Product Highlights

• Combines three antiretroviral medications into one daily pill.
• Simplifies HIV treatment by reducing the number of pills needed.
• Helps to maintain low levels of HIV in the blood and improve immune function.

Key Ingredients

• Efavirenz: An NNRTI (non-nucleoside reverse transcriptase inhibitor) that works by inhibiting the reverse transcriptase enzyme crucial for the replication of HIV.
• Emtricitabine: A NRTI (nucleoside reverse transcriptase inhibitor) that blocks reverse transcriptase, preventing the conversion of HIV RNA into DNA.
• Tenofovir: A NRTI that also inhibits reverse transcriptase and disrupts the HIV replication cycle.

Key Benefits

• Reduces the viral load of HIV-1, helps in increasing CD4 cell counts.
• Once-daily dosing helps improve adherence to treatment.
• Combines drugs with different mechanisms of action for more effective viral suppression.

Direction For Use

• Typically, one tablet is taken once daily, with or without food. The specific dose and frequency should be prescribed by a healthcare provider based on individual needs.
• It's important to take the medication at the same time each day to maintain consistent drug levels in the body.

Safety Concern

• Common side effects include dizziness, insomnia, and rash. More serious effects can include liver toxicity, kidney issues, and psychiatric symptoms.
• Efavirenz can interact with various medications, potentially affecting their effectiveness or increasing side effects. It’s important to inform your healthcare provider of all other medications being taken.

Avoid Atripla (Efavirenz / Emtricitabine / Tenofovir) If

• If you have a known allergy to efavirenz, emtricitabine, tenofovir, or any other components of the medication.
• People with severe liver disease, certain kidney conditions, or a history of mental health disorders may need to avoid Atripla or use it with caution.
• It should be used during pregnancy only if clearly needed, and under the guidance of a healthcare provider, as efavirenz can potentially harm the fetus.